2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Thyroid Cancer, Papillary
2
Polycystic Ovary Syndrome
2
Pituitary Neoplasms
2
Neoplasms
2
Diabetes Mellitus, Type 2
2
Adenocarcinoma, Follicular
2
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Cancers
1
Sezary Syndrome
1
Sarcoma
1
Prostatic Neoplasms
1
Pituitary ACTH Hypersecretion
1
Pancreatic Neoplasms
1
Obesity
1
Mycosis Fungoides
1
Melanoma
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Follicular
1
Liposarcoma
1
Leukoplakia, Oral
1
Head and Neck Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Alzheimer Disease
1
Adenocarcinoma Of Esophagus
1
Interventions
pembrolizumab
185
Gemcitabine
170
Paclitaxel
152
Carboplatin
137
Bevacizumab
128
Surveys and Questionnaires
118
Cisplatin
115
Docetaxel
114
Blood Specimen Collection
110
Cyclophosphamide
109
Exercise
108
Nivolumab
99
Fluorouracil
90
Capecitabine
86
Radiotherapy
81
Dexamethasone
81
Irinotecan
74
Standard of Care
69
Pemetrexed
68
Oxaliplatin
68
Drug Therapy
65
Leucovorin
64
Cetuximab
60
Erlotinib Hydrochloride
56
atezolizumab
53
Sorafenib
53
Ipilimumab
51
Doxorubicin
50
trametinib
47
Interviews as Topic
47
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Neoplasms
×
Rosiglitazone
×
Clear all
NCT01287598
2019-07-10
BAY73-4506 Probe Substrate Study
Bayer
Phase 1
Completed
41 enrolled
NCT01195259
2013-10-28
Malignancy Meta Analysis for BRL49653
GlaxoSmithKline
Completed
1 enrolled